These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 35965206)
1. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206 [TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956 [TBL] [Abstract][Full Text] [Related]
3. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431 [TBL] [Abstract][Full Text] [Related]
4. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Plimack ER; Tangen C; Plets M; Kokate R; Xiu J; Nabhan C; Ross EA; Grundy E; Choi W; Dinney CPN; Lee IC; Fong M; Scott Lucia M; Daneshmand S; Theodorescu D; Goldkorn A; Lerner SP; Flaig TW; McConkey DJ Eur Urol; 2024 Oct; 86(4):297-300. PubMed ID: 39003201 [TBL] [Abstract][Full Text] [Related]
6. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205 [TBL] [Abstract][Full Text] [Related]
7. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer. Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965 [TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762 [TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554 [TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Teo MY; Guercio BJ; Arora A; Hao X; Regazzi AM; Donahue T; Herr HW; Goh AC; Cha EK; Pietzak E; Donat SM; Dalbagni G; Bochner BH; Olgac S; Sarungbam J; Sirintrapun SJ; Chen YB; Gopalan A; Fine SW; Tickoo SK; Reuter VE; Weigelt B; Schultheis AM; Funt SA; Bajorin DF; Solit DB; Iyer G; Ostrovnaya I; Rosenberg JE; Al-Ahmadie H Clin Genitourin Cancer; 2022 Oct; 20(5):431-441. PubMed ID: 35676169 [TBL] [Abstract][Full Text] [Related]
12. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial. Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822 [TBL] [Abstract][Full Text] [Related]
13. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer. Beckabir W; Wobker SE; Damrauer JS; Midkiff B; De la Cruz G; Makarov V; Flick L; Woodcock MG; Grivas P; Bjurlin MA; Harrison MR; Vincent BG; Rose TL; Gupta S; Kim WY; Milowsky MI Eur Urol; 2024 Mar; 85(3):242-253. PubMed ID: 38092611 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we? Osanto S; Álvarez Gómez de Segura C Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716 [TBL] [Abstract][Full Text] [Related]
16. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065 [TBL] [Abstract][Full Text] [Related]